TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL

The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents, such as anti-CD19/CD3 bispecific T-cell engager b...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:MAbs
Huvudupphovsmän: Malik-Chaudhry, Harbani K., Prabhakar, Kirthana, Ugamraj, Harshad S., Boudreau, Andrew A., Buelow, Benjamin, Dang, Kevin, Davison, Laura M., Harris, Katherine E., Jorgensen, Brett, Ogana, Heather, Pham, Duy, Schellenberger, Ute, Van Schooten, Wim, Buelow, Roland, Iyer, Suhasini, Trinklein, Nathan D., Rangaswamy, Udaya S.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Taylor & Francis 2021
Ämnen:
Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8023237/
https://ncbi.nlm.nih.gov/pubmed/33818299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2021.1890411
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk